Digital ILC 2021 kicks off one week from today, with four days of sessions covering the entire range of liver topics. Professor Schattenberg joins Dr. Stephen Harrison, Louise Campbell and Roger Green in identifying presentations, sessions and major themes they believe will import new knowledge and even change the ways we look at NAFLD and NASH. Want to get revved up for the Congress? Listen here.

TOPICS: Akero Therapeutics, aldafermin, cirrhosis, COVID-19, Diabetes, Diagnostic Tests, EASL, education, efruxifermin, FDA, Fibrosis Level 3, Fibrosis Level 4, Global Liver Institute, Intercept Pharmaceuticals, inventiva, lanifibranor, Lean NASH, Madrigal, NAFLD, NASH, non-invasive liver testing, OCA, Patient Advocacy, Phase3, population screening, social policy, ILC 2021, resmetirom, selonsertib, omega-3 fatty acids, omega-6 fatty acids, food insecurity

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast